Литература
1. URL: http://www.who.int/ru/news-room/fact-sheets/detail/the-top-10-causes-of-death.
2. Таратухин Е.О., Гордеев И.Г., Лебедева А.Ю. Психосоматический порочный круг инфаркта миокарда // Рос. кардиол. журн. 2018. № 1. (153). C. 83-88. URL: http://dx.doi.org/10.15829/1560-4071-2018-1-83-88.
3. URL: http://www.who.int/ru/news-room/fact-sheets/detail/the-top-10-causes-of-death.
4. Российский статистический ежегодник. 2017 : статистический сборник. М. : Росстат, 2017. 686 с.
5. Демографический ежегодник РФ. 2017 : статистический сборник. М. : Росстат, 2017. 263 c.
6. URL: http://icosna.org/past-events/
7. URL: http://www.scardio.ru/content/sections/Cardioonkologiya_Otchet_o_pervom_zasedanii.pdf.
8. Берштейн Л. М. Эндокринные и сопряженные с ними последствия консервативного (химиогормонотерапевтического) лечения онкологических больных: возможности и степень целесообразности коррекции // Злокачественные опухоли. 2013. № 2. С. 12-17. URL; https://doi.org/10.18027/2224-5057-2013-2-12-17.
9. Zoller B., Ji J., Sundquist J. et al. Risk of coronary heart disease in patients with cancer: a nationwide follow-up study from Sweden // Eur. J. Cancer. 2012. Vol. 48. P. 121-128.
10. Van Nimwegen F.A., Schaapveld M., Janus C.P. et al. Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk // JAMA Intern. Med 2015. Vol. 175. P. 1007-1017.
11. Мкртчян В.Р. Сравнительная характеристика гормонального профиля женщин при вегетативно-дисгормональной миокардиодистрофии различного генеза // Рос. кардиол. журн. 2005. № 6. C. 29-34.
12. Lin Y.N., Chang Y.J., Chen Y.H. et al. Nationwide population based cohort study on the association of acute coronary syndrome in patients with malignancies // Support. Care Cancer. 2014. Vol. 22, N 10. P. 2707-2713.
13. Green D., Kwaan H.C. Coagulation in Cancer. Springer Science Business Media, 2009. 339 p. doi: 10.1007/978-0-387-79962-9.
14. Свиридова С.П., Сомонова О.В., Сытов А.В., Чучуев Е.С. Рак, тромбозы и гепарины - современное состояние проблем // Вестник РОНЦ им. Н.Н. Блохина РАМН. 2013. Т. 24, № 2. С. 11-20.
15. Петрова О.Ю., Суханов В.А., Левит Д.А. Гипофибринолиз как основной фактор риска тромбоэмболических осложнений у онкологических пациентов // Злокачественные опухоли. 2014. № 3 (10). C. 147-154.
16. Рукояткина Н.И., Баллюзек М.Ф., Якимов Е.Н., Судницына Ю.С. и др. Механизм развития апоптоза тромбоцитов при действии противоопухолевых препаратов: ABT-737 и тимокинона // Гематол. и трансфузиол. 2016. Т. 61, № 1. С. 167.
17. Kuter D.J. Managing thrombocytopenia associated with cancer chemotherapy // Oncology (Williston Park). 2015. Vol. 29, N 4. P. 282-294.
18. Шелепова В.М. Использование опухолевых маркеров в диагностике новообразований при паранеопластических синдромах // Врач. 2010. № 11. С. 65-69.
19. Luis Zamorano J., Lancellotti P., Rodriguez Muñoz D. et al. Меморандум ESC по лечению онкологических заболеваний и сердечно-сосудистой токсичности, разработанный под эгидой комитета по практике ESC 2016 // Рос. кардиол. журн. 2017. № 3 (143). С. 105-139. URL: http://dx.doi.org/10.15829/1560-4071-2017-3-105-139.
20. Поповкина О.Е., Потиевская В.И., Шкляева А.В. Лечение кардиотоксичности в онкологической клинике // Материалы IV Петербургского Международного Онкологического форума "Белые ночи 2018". СПб., 2018. С. 185.
21. Баллюзек М.Ф., Ионова А.К. Кардиоонкология в программах лечениях и реабилитации онкологических больных // Рос. кардиол. журн. 2014. № 5 (109). C. 75-80.
22. Явелов И.С., Хохлунов С.М., Дупляков Д.В. Острый коронарный синдром. М. : ГЭОТАР-Медиа. 2017. 384 c.
23. Рабочая группа по ведению пациентов с острым инфарктом миокарда с подъемом сегмента ST Европейского общества кардиологов (ЕОК). Рекомендации ЕОК по ведению пациентов с острым инфарктом миокарда с подъемом сегмента ST 2017 // Рос. кардиол. журн. 2018. № 5 (157). С. 103-158. URL: http://dx.doi.org/10.15829/1560-4071-2018-5-103-158.
24. Yusuf S.W., Daraban N., Abbasi N. et al. Treatment and outcomes of acute coronary syndrome in the cancer population // Clin. Cardiol. 2012. Vol. 35. P. 443-450.
25. Рабочая группа Европейского кардиологического общества (ESC) по ведению пациентов с острым коронарным синдромом без стойкого подъема сегмента ST. Рекомендации ESC по ведению пациентов с острым коронарным синдромом без стойкого подъема сегмента ST 2015 // Рос. кардиол. журн. 2016. № 3 (131). С. 9-63. URL: http://dx.doi.org/10.15829/1560-4071-2016-3-9-63.
26. Than M.P., Aldous S.J., Troughton R.W. et al. Detectable high-sensitivity cardiac troponin within the population reference interval conveys high 5-year cardiovascular risk: an observational study // Clin. Chem. 2018 Vol. 64, N 7. P. 1044-1053. doi: 10.1373/clinchem.2017.285700.
27. Corteville D.C., Armstrong D.F., Montgomery D.G. et al. Treatment and outcomes of first troponinnegative non-ST-segment elevation myocardial infarction // Am. J. Cardiol. 2011. Vol. 107. P. 24-29.
28. Лубоятникова Е.С., Дупляков Д.В. Острый коронарный синдром у пациентов со злокачественными новообразованиями // Рос. кардиол. журн. 2017. № 3 (143). С. 140-144. URL: http://dx.doi.org/10.15829/1560-4071-2017-3-140-144.
29. Separham A., Abbasnezhad M., Shahnazarli G., Khoshbahar A. Role of plasma levels of CA-125 in predicting outcome of primary PCI after acute myocardial infarction in male patients // J. Cardiovasc. Thorac. Res. 2018. Vol. 10, N 2. P. 109-112. doi: 10.15171/jcvtr.2018.17.
30. Yu D., Cai Y., Zhou W. et al. The potential of Angiogenin as a serum biomarker for diseases: systematic review and meta-analysis // Dis. Markers. 2018. Vol. 1. P. 15. doi: 10.1155/2018/1984718.
31. Kohli P., Bonaca M.P., Kakkar R. et al. Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial // Clin. Chem. 2012. Vol. 58, N 1. P. 257-266. doi: 10.1373/clinchem.2011.173369.
32. Argmann C.A., Van Den Diepstraten C.H., Sawyez C.G. et al. Transforming growth factor-beta 1 inhibits macrophage cholesterol ester accumulation induced by native and oxidized VLDL remnants // Arterioscler. Thromb. Vasc. Biol. 2001. Vol. 21, N 12. P. 2011-2018.
33. Zimmers T., Jin X., Hsiao E. et al. Growth differentiation factor-15/macrophage inhibitory cytokine-1 induction after kidney and lung injury // Shock. 2005. Vol. 23, N 6. P. 543-548.
34. Liu D.D., Mei Y.A. Effects of growth differentiation factor-15 (GDF-15) on neurological systems, cardiovascular diseases, and cancer progression // Sheng Li Xue Bao. 2017. Vol. 69, N 1. P. 109-121.
35. Дегтярева А.В., Степанова Е.В., Иткис Ю.С., Дорофеева Е.И., Нароган М.В., Ушакова Л.В., Пучкова А.А., Быченко В.Г., Цыганкова П.Г., Крылова Т.Д., Бычков И.О. Клиническое наблюдение пациента с синдромом истощения митохондриальной ДНК // Рос. вестн. перинатол. и педиатр. 2017. № 6 (62). С. 55-62. doi: 10.21508/1027-4065-2017-62-5-55-62. (in Russian)
36. Mimeault M., Batra S.K. Divergent molecular mechanisms underlying the pleiotropic functions of macrophage inhibitory cytokine-1 in cancer // J. Cell. Physiol. 2010. Vol. 224, N 3. P. 626-635. doi: 10.1002/jcp.22196. PMID 20578239.
37. Zhang S., Dai D., Wang X. et al. Growth differentiation factor-15 predicts the prognoses of patients with acute coronary syndrome: a meta-analysis // BMC Cardiovasc. Disord. 2016. Vol. 16. P. 82. doi: 10.1186/s12872-016-0250-2.
38. Саенко Ю.В., Глущенко Е.С., Антонова А.В., Живодерников И.В. и др. Изучение динамики транскриптома раковых клеток с нормальным и мутантным геном tp53 в условиях радиационно-индуцированного оксидативного стресса // Ульяновский мед.-биол. журн. 2013. № 4. С. 86-92.
39. Proutski I., Stevenson L., Allen W.L. et al. Prostate-derived factor - a novel inhibitor of drug-induced cell death in colon cancer cells // Mol. Cancer Ther. 2009. Vol. 8, N 9. P. 2566-2574. doi: 10.1158 / 1535-7163.MCT-09-0158.
40. Хавинсон В.Х., Кузник Б.И., Линькова Н.С., Колчина Н.В. Роль цитокина MIC-1/GDF15 в развитии заболеваний у лиц пожилого возраста (обзор литературы и собственных данных) // Успехи физиол. наук. 2015. Т. 46, № 4. С. 38-52.
41. Foley P.W., Stegemann B., Ng K. et al. Differentiation factor-15 predicts mortality and morbidity after cardiac resynchronization therapy // Eur. Heart J. 2009. Vol. 30. P. 2749-2757.
42. Koopmann J., Buckhaults P., Brown D.A. et al. Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers // Clin. Cancer Res. 2004. Vol. 10, N 6. P. 2386-2392.
43. Corre J., Hebraud B., Bourin P. Concise review: growth differentiation factor 15 in pathology: a clinical role // Stem Cells Transl. Med. 2013. Vol. 2, N 12. P. 946-952. doi: 10.5966 / sctm.2013-0055.
44. Shnaper S., Desbaillets I., Brown D.A. et al. Elevated levels of MIC-1/GDF15 in the cerebrospinal fluid of patients are associated with glioblastoma and worse outcome // Int. J. Cancer. 2009. Vol. 125, N 11. P. 2624-2630. doi: 10.1002 / ijc.24639.
45. Lu Z., Yang L., Yu J. et al. Change of body weight and macrophage inhibitory cytokine-1 during chemotherapy in advanced gastric cancer: what is their clinical significance // PLoS One. 2014. Vol. 9, N 2. P. 1-9. doi: 10.1371 / journal.pone.0088553.
46. Staff A.C., Trovik J., Eriksson A.G. et al. Elevated plasma growth differentiation factor-15 correlates with lymph node metastases and poor survival in endometrial cancer // Clin. Cancer Res. 2011. Vol. 17, N 14. P. 4825-4833. doi: 10.1158/1078-0432.CCR-11-0715.
47. Yang C.Z., Ma J., Luo Q.Q. et al. Elevated level of serum growth differentiation factor 15 is associated with oral leukoplakia and oral squamous cell carcinoma // J. Oral Pathol. Med. 2014. Vol. 43, N 1. P. 28-34. doi: 10.1111/jop.12091.
48. Tsui K.H., Chang Y.L., Feng T.H. et al. Growth differentiation factor-15 upregulates interleukin-6 to promote tumorigenesis of prostatecarcinoma PC-3 cells // J. Mol. Endocrinol. 2012. Vol. 49, N 2. P. 153-163. doi: 10.1530/JME-11-0149.
49. Putt M. et al. Longitudinal changes in multiple biomarkers are associated with cardiotoxicity in breast cancer patients treated with doxorubicin, taxanes, and trastuzumab // Clin. Chem. 2015. Vol. 61, N 9. P. 1164-1172.
50. Kempf T., Eden M., Strelau J. et al. The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury // Circ. Res. 2006. Vol. 98, N 3. P. 351-360.
51. Lee E.S., Kim S.H., Kim H.J. et al. Growth differentiation factor 15 predicts chronic liver disease severity // Gut Liver. 2017. Vol. 11, N 2. P. 276-282. doi: 10.5009/gnl16049.
52. Gamal S.M., Elgengehy F.T., Kamal A. et al. Growth differentiation factor-15 (GDF-15) level and relation to clinical manifestations in systemic sclerosis patients: preliminary data // Immunol. Invest. 2017. Vol. 46, N 7. P. 703-713. doi: 10.1080/08820139.2017.1360340.
53. Li J., Cui Y., Huang A. et al. Additional diagnostic value of growth differentiation factor-15 (GDF-15) to N-Terminal B-type natriuretic peptide (NT-proBNP) in patients with different stages of heart failure // Med. Sci. Monit. 2018. Vol. 24. P. 4992-4999. doi: 10.12659/MSM.910671.
54. Kempf T., Wollert K. Growth differentiation factor-15 in heart failure // Heart Fail. Clin. 2009. Vol. 5, N 4. P. 537-547. doi:10.1016/j.hfc.2009.04.006.
55. Baessler A., Strack C., Rousseva E. et al. Growth-differentiation factor-15 improves reclassification for the diagnosis of heart failure with normal ejection fraction in morbid obesity // Eur. J. Heart Fail. 2012. Vol. 14, N 11. P. 1240-1248. doi:10.1093/eurjhf/ hfs116.
56. Arslan D. et al. Growth-differentiation factor-15 and tissue Doppler ımaging in detection of asymptomatic anthracycline cardiomyopathy in childhood cancer survivors // Clin. Biochem. 2013. Vol. 46, N 13-14. P. 1239-1243.
57. Bouabdallaoui N., Claggett B., Zile M.R. et al. Growth differentiation factor-15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction: the PARADIGM-HF trial // Eur. J. Heart Fail. 2018 Sep 11. doi: 10.1002/ejhf.1301.
58. Stahrenberg R., Edelmann F., Mende M. et al. The novel biomarker growth differentiation factor 15 in heart failure with normal ejection fraction // Eur. J. Heart Fail. 2010. Vol. 12, N 12. P. 1309-1316. doi: 10.1093/eurjhf/hfq151.
59. Мареев В.Ю., Фомин И.В., Агеев Ф.Т и др. Клинические рекомендации. Хроническая сердечная недостаточность // Сердечная недостаточность. 2017. Т. 18, № 1. С. 3-40. doi: 10.18087/rhfj.2017.1.2346.
60. Сыволап В.Д., Земляной Я.В. Взаимосвязь ростового фактора дифференцировки 15, N-терминального фрагмента мозгового натрийуретического пептида с ремоделированием сердца у больных сердечной недостаточностью с сохраненной фракцией выброса после перенесенного инфаркта миокарда с артериальной гипертензией // Медицина. Фармация. 2014. № 18 (189). С. 68-73.
61. Stahrenberg R., Edelmann F., Mende M. et al. The novel biomarker growth differentiation factor 15 in heart failure with normal ejection fraction // Eur. J. Heart Fail. 2010. Vol. 12, N 12. P. 1309-1316. doi: 10.1093/eurjhf/hfq151.
62. Bettencourt P., Ferreira-Coimbra J., Rodrigues P. et al. Towards a multi-marker prognostic strategy in acute heart failure: a role for GDF-15 // ESC Heart Fail. 2018. doi: 10.1002/ehf2.12301.
63. Хоролец Е.В., Шлык С.В. Особенности GDF-15 у больных острым инфарктом миокарда осложненный острой сердечной недостаточностью // VI Евразийский конгресс кардиологов : тезисы. М., 2018. С. 39.
64. Копица Н.П., Вишневская И.Р. Прогнозирование летального исхода у больных острым коронарным синдромом в ближайший и отдаленный периоды // Sciencerisi. 2014. Т. 5, № 4. С. 7-10. doi: 10.15587/2313-8416.2014.31916.
65. Kempf T., Bjorklund E., Olofsson S. et al. Growth-differentiation factor-15 improves risk stratification in ST-segment elevation myocardial infarction // Eur. Heart J. 2007. Vol. 28, N 23. P. 2858-2865. doi: 10.1093/eurheartj/ehm465.
66. Garcia-Garcia C., Rueda F., Lupon J. et al. Growth differentiation factor-15 is a predictive biomarker in primary ventricular fibrillation: the RUTI-STEMI-PVF study // Eur. Heart J. Acute Cardiovasc Care. 2018 Sep 3. doi: 10.1177/2048872618797599.
67. Wollert K.C., Kempf T., Peter T. et al. Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome // Circulation. 2007. Vol. 115, N 8. P. 962-971.
68. Damman P., Kempf T., Windhausen F. et al. Growth-differentiation factor 15 for long-term prognostication in patients with non-ST-elevation acute coronary syndrome: an Invasive versus Conservative Treatment in Unstable coronary Syndromes (ICTUS) substudy // Int. J. Cardiol. 2014. Vol. 172, N 2. P. 356-363. doi: 10.1016/j.ijcard.2014.01.025.
69. Sun L., Zhou X., Jiang J. et al. Growth differentiation factor-15 levels and the risk of contrast induced acute kidney injury in acute myocardial infarction patients treated invasively: a propensity-score match analysis // PLoS One. 2018. Vol. 13, N 3. doi: 10.1371/journal.pone.0194152.
70. Копица Н.П. Роль ростового фактора дифференцировки 15 в стратификации риска повреждения почек при остром коронарном синдроме // Актуал. пробл. сучасн. мед.: Вісн. Укр. мед. стомат. акад. 2017. Т. 17, № 1. С. 106-111.
71. Lindholm D., Hagström E., James S.K. et al. Growth differentiation factor 15 at 1 month after an acute coronary syndrome is associated with increased risk of major bleeding // J. Am. Heart Assoc. 2017. Vol. 6, N 4. doi: 10.1161/JAHA.117.005580.
References
1. URL: http://www.who.int/ru/news-room/fact-sheets/detail/the-top-10-causes-of-death.
2. Taratukhin E.O., Gordeev I.G., Lebedev A.Y. Psychosomatic vicious circle of myocardial infarction. Rossiyskiy kardiologicheskiy zhurnal [Russian Journal of Cardiology]. 2018; 1 (153): 83-8. URL: http://dx.doi.org/10.15829/1560-4071-2018-1-83-88. (in Russian)
3. URL: http://www.who.int/ru/news-room/fact-sheets/detail/the-top-10-causes-of-death.
4. Russian statistical yearbook: statistical compendium. Moscow: Rosstat, 2017: 686 p. (in Russian)
5. Demographic Yearbook of the Russian Federation: statistical compendium. Moscow: Rosstat, 2017: 263 p. (in Russian)
6. URL: http://icosna.org/past-events/
7. URL: http://www.scardio.ru/content/sections/Cardioonkologiya_Otchet_o_pervom_zasedanii.pdf.
8. Bershtein L.M. Endocrine and related consequences of the conservative (himagromarketing) of cancer treatment: opportunities and the degree of appropriateness of correction. Zlokachestvennye opukholi [Malignant Tumours]. 2013; (2): 12-7. URL: https://doi.org/10.18027/2224-5057-2013-2-12-17. (in Russian)
9. Zoller B., Ji J., Sundquist J., et al. Risk of coronary heart disease in patients with cancer:
a nationwide follow-up study from Sweden. Eur J Cancer. 2012; 48: 121-8.
10. Van Nimwegen F.A., Schaapveld M., Janus C. P., et al. Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk. JAMA Intern Med 2015; 175: 1007-17.
11. Mkrtchyan V.R. Comparative characteristics of hormonal profile of women with vegetative-dishormonal myocardiodystrophy of different genesis. Rossiyskiy kardiologicheskiy zhurnal [Russian Journal of Cardiology]. 2005; (6): 29-34. (in Russian)
12. Lin Y.N., Chang Y.J., Chen Y.H., et al. Nationwide population based cohort study on the association of acute coronary syndrome in patients with malignances. Support Care Cancer. 2014; 22 (10): 2707-13.
13. Green D., Kwaan H.C. Coagulation in cancer. Springer Science Business Media, 2009: 339 p. doi: 10.1007/978-0-387-79962-9.
14. Sviridov S.P., Simonova O.V., Sytov V.A., Chuchuev E.S. Cancer, thrombosis and heparin - contemporary state of problem. Vestnik Ronts imeni N.N. Blokhina RAMN [Bulletin of RONTs named after N.N. Blokhin of the RAMS]. 2013; 24 (2): 11-20. (in Russian)
15. Petrova O.Yu., Sukhanov V.A., Levite D.A. Hypofibrinolysis as a major risk factor of thromboembolism in cancer patients. Zlokachestvennye opukholi [Malignant Tumours ]. 2014; 3 (10): 147-54. (in Russian)
16. Roukoyatkina N.I., Ballyuzek M.F., Yakimov E.N., Sudnitsyna Y.S., et al. Mechanism of the apoptosis of platelets by the action of anticancer drugs: AVT-737 and Timokhina. Gematologiya i transfuziologiya [Hematology and Transfusiology]. 2016; 61 (1): 167. (in Russian)
17. Kuter D.J. Managing thrombocytopenia associated with cancer chemotherapy // Oncology (Williston Park). 2015; 29 (4): 282-94.
18. Shelepova V.M. The use of tumor markers in the diagnosis of tumors in paraneoplastic syndromes. Vrach [Physician]. 2010; (11): 65-9. (in Russian)
19. Luis Zamorano J., Lancellotti P., Rodriguez Muñoz D., et al. ESC Memorandum on cancer treatment and cardiovascular toxicity developed under the auspices of the ESC Committee for practice 2016. Rossiyskiy kardiologicheskiy zhurnal [Russian Journal of Cardiology]. 2017; 3 (143): 105-39. URL: http://dx.doi.org/10.15829/1560-4071-2017-3-105-139. (in Russian)
20. Popovkin O.E., Putievsky V.I., Shklyaeva A.V. Treatment of cardiotoxicity oncology clinic. In: Proceedings of the IV St. Petersburg International Oncology forum "White Nights 2018". Saint Petersburg, 2018: 185. (in Russian)
21. Ballyuzek M.F., Ionov A.K. Cardiooncology in programs of treatment and rehabilitation onkologicheskih patients. Rossiyskiy kardiologicheskiy zhurnal [Russian Journal of Cardiology]. 2014; 5 (109): 75-80. (in Russian)
22. Yavelov I.S., Khokhlunov S.M., Duplyakov D.V. Acute coronary syndrome. Moscow: GEOTAR-Media, 2017: 384 p. (in Russian)
23. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation.The task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Russ J Cardiol. 2018; 157 (5): 103-58. URL: http://dx.doi.org/10.15829/1560-4071-2018-5-103-158.
24. Yusuf S.W., Daraban N., Abbasi N., et al. Treatment and outcomes of acute coronary syndrome in the cancer population. Clin Cardiol. 2012; 35: 443-50.
25. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation - Web Addenda. Task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Russ J Cardiol. 2016; 3 (131): 9-63. URL: http://dx.doi.org/10.15829/1560-4071-2016-3-9-63.
26. Than M.P., Aldous S.J., Troughton R.W., et al. Detectable high-sensitivity cardiac troponin within the population reference interval conveys high 5-year cardiovascular risk: an observational study. Clin Chem. 2018; 64 (7): 1044-53. doi: 10.1373/clinchem.2017.285700.
27. Corteville D.C., Armstrong D.F., Montgomery D.G., et al. Treatment and outcomes of first troponinnegative non-ST-segment elevation myocardial infarction. Am J Cardiol. 2011; 107: 24-9.
28. Libatique E.S., Duplyakov D.V. Acute coronary syndrome in patients with malignant tumors. Rossiyskiy kardiologicheskiy zhurnal [Russian Journal of Cardiology]. 2017; 3 (143): 140-4. URL; http://dx.doi.org/10.15829/1560-4071-2017-3-140-144. (in Russian)
29. Separham A., Abbasnezhad M., Shahnazarli G., Khoshbahar A. Role of plasma levels of CA-125 in predicting outcome of primary PCI after acute myocardial infarction in male patients. J Cardiovasc Thorac Res. 2018; 10 (2): 109-12. doi: 10.15171/jcvtr.2018.17.
30. Yu D., Cai Y., Zhou W., et al. The potential of Angiogenin as a serum biomarker for diseases: systematic review and meta-analysis. Dis Markers. 2018; 1: 15. doi: 10.1155/2018/1984718.
31. Kohli P., Bonaca M.P., Kakkar R., et al. Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial. Clin Chem. 2012: 58 (1): 257-66. doi: 10.1373/clinchem.2011.173369.
32. Argmann C.A., Van Den Diepstraten C.H., Sawyez C.G., et al. Transforming growth factor-beta 1 inhibits macrophage cholesterol ester accumulation induced by native and oxidized VLDL remnants. Arterioscler Thromb Vasc Biol. 2001; 21 (12): 2011-8.
33. Zimmers T., Jin X., Hsiao E., et al. Growth differentiation factor-15/macrophage inhibitory cytokine-1 induction after kidney and lung injury. Shock. 2005; 23 (6): 543-8.
34. Liu D.D., Mei Y.A. Effects of growth differentiation factor-15 (GDF-15) on neurological systems, cardiovascular diseases, and cancer progression. Sheng Li Xue Bao. 2017; 69 (1): 109-21.
35. Degtyareva A.V., Stepanova E.V., Itkis Yu.S., et al. Clinical case of FBXL4-related encephalomyopathic mitochondrial DNA depletion. Rossiyskiy vestnik perinatologii i pediatrii [Russian Bulletin of Perinatology and Pediatrics]. 2017; 62 (5): 55-62. doi: 10.21508/1027-4065-2017-62-5-55-62. (in Russian)почему в литературе не на русском?
36. Mimeault M., Batra S.K. Divergent molecular mechanisms underlying the pleiotropic functions of macrophage inhibitory cytokine-1 in cancer. J Cell Physiol. 2010; 224 (3): 626-35. doi: 10.1002/jcp.22196. PMID 20578239.
37. Zhang S., Dai D., Wang X., et al. Growth differentiation factor-15 predicts the prognoses of patients with acute coronary syndrome: a meta-analysis. BMC Cardiovasc Disord. 2016; 16: 82. doi: 10.1186/s12872-016-0250-2.
38. Saenko V., Glushchenko E.S., Antonov A.V., Zivadinov I.V., et al. Study of the dynamics of the transcriptome of cancer cells with normal and mutant gene tp53 in radiation-induced oxidative stress. Ul’yanovskiy mediko-biologicheskiy zhurnal [Medical and Biological Journal of Ul’yanovsk]. 2013; (4): 86-92. (in Russian)
39. Proutski I., Stevenson L., Allen W.L., et al. Prostate-derived factor-a novel inhibitor of drug-induced cell death in colon cancer cells. Mol Cancer Ther. 2009; 8 (9): 2566-74. doi: 10.1158 / 1535-7163.MCT-09-0158/
40. Khavinson V.H., Kuznik B.I., Linkova N.S., Kolchina N.V. The role of cytokine MIC-1/GDF15 in the development of diseases in the elderly (review of literature and own data). Uspekhi fiziologicheskikh nauk [Progress in the Physiological Sciences]. 2015; 46 (4): 38-52. (in Russian)
41. Foley P.W., Stegemann B., Ng K., et al. Differentiation factor-15 predicts mortality and morbidity after cardiac resynchronization therapy. Eur Heart J. 2009; 30: 2749-57.
42. Koopmann J., Buckhaults P., Brown D.A., et al. Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers. Clin Cancer Res. 2004; 10 (6): 2386-92.
43. Corre J., Hebraud B., Bourin P. Concise review: growth differentiation factor 15 in pathology: a clinical role. Stem Cells Transl Med. 2013; 2 (12): 946-52. doi: 10.5966 / sctm.2013-0055.
44. Shnaper S., Desbaillets I., Brown D.A., et al. Elevated levels of MIC-1/GDF15 in the cerebrospinal fluid of patients are associated with glioblastoma and worse outcome. Int J Cancer. 2009; 125 (11): 2624-30. doi: 10.1002 / ijc.24639.
45. Lu Z., Yang L., Yu J., et al. Change of body weight and macrophage inhibitory cytokine-1 during chemotherapy in advanced gastric cancer: what is their clinical significance. PLoS One. 2014; 9 (2): 1-9. doi: 10.1371 / journal.pone.0088553.
46. Staff A.C., Trovik J., Eriksson A.G., et al. Elevated plasma growth differentiation factor-15 correlates with lymph node metastases and poor survival in endometrial cancer. Clin Cancer Res. 2011; 17 (14): 4825-33. doi: 10.1158/1078-0432.CCR-11-0715.
47. Yang C.Z., Ma J., Luo Q.Q., et al. Elevated level of serum growth differentiation factor 15 is associated with oral leukoplakia and oral squamous cell carcinoma. J Oral Pathol Med. 2014; 43 (1): 28-34. doi: 10.1111/jop.12091.
48. Tsui K.H., Chang Y.L., Feng T.H., et al. Growth differentiation factor-15 upregulates interleukin-6 to promote tumorigenesis of prostatecarcinoma PC-3 cells. J Mol Endocrinol. 2012; 49 (2): 153-63. doi: 10.1530/JME-11-0149.
49. Putt M., et al. Longitudinal changes in multiple biomarkers are associated with cardiotoxicity in breast cancer patients treated with doxorubicin, taxanes, and trastuzumab. Clin Chem. 2015; 61 (9): 1164-72.
50. Kempf T., Eden M., Strelau J., et al. The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury. Circ Res. 2006; 98 (3): 351-60.
51. Lee E.S., Kim S.H., Kim H.J., et al. Growth differentiation factor 15 predicts chronic liver disease severity. Gut Liver. 2017; 11 (2): 276-82. doi: 10.5009/gnl16049.
52. Gamal S.M., Elgengehy F.T., Kamal A., et al. Growth differentiation factor-15 (GDF-15) level and relation to clinical manifestations in systemic sclerosis patients: preliminary data. Immunol Invest. 2017; 46 (7): 703-13. doi: 10.1080/08820139.2017.1360340.
53. Li J., Cui Y., Huang A., et al. Additional diagnostic value of growth differentiation factor-15 (GDF-15) to N-Terminal B-type natriuretic peptide (NT-proBNP) in patients with different stages of heart failure. Med Sci Monit. 2018; 24: 4992-9. doi: 10.12659/MSM.910671.
54. Kempf T., Wollert K. Growth differentiation factor-15 in heart failure. Heart Fail Clin. 2009; 5 (4): 537-47. doi:10.1016/j.hfc.2009.04.006.
55. Baessler A., Strack C., Rousseva E., et al. Growth-differentiation factor-15 improves reclassification for the diagnosis of heart failure with normal ejection fraction in morbid obesity. Eur J Heart Fail. 2012; 14 (11): 1240-8. doi:10.1093/eurjhf/ hfs116.
56. Arslan D., et al. Growth-differentiation factor-15 and tissue Doppler ımaging in detection of asymptomatic anthracycline cardiomyopathy in childhood cancer survivors. Clin Biochem. 2013; 46 (13-14): 1239-43.
57. Bouabdallaoui N., Claggett B., Zile M.R., et al. Growth differentiation factor-15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction: the PARADIGM-HF trial. Eur J Heart Fail. 2018 Sep 11. doi: 10.1002/ejhf.1301.
58. Stahrenberg R., Edelmann F., Mende M., et al. The novel biomarker growth differentiation factor 15 in heart failure with normal ejection fraction. Eur J Heart Fail. 2010; 12 (12): 1309-16. doi: 10.1093/eurjhf/hfq151.
59. Mareev V.Yu., Fomin I.V., Ageev F.T., et al. Clinical guidelines. Chronic heart failure. Serdechnaya nedostatochnost’ [Heart Failure]. 2017; 18 (1). doi: 10.18087/rhfj.2017.1.2346. (in Russian)
60. Syvolap V.D., Earthy J.V. The relationship of the growth differentiation factor 15, N-terminal fragment of brain natriuretic peptide with cardiac remodeling in patients with heart failure with preserved ejection fraction after myocardial infarction with arterial hypertension. Meditsina. Farmatsiya [Medicine. Pharmacy]. 2014; 18 (189): 68-73. (in Russian)
61. Stahrenberg R., Edelmann F., Mende M., et al. The novel biomarker growth differentiation factor 15 in heart failure with normal ejection fraction. Eur J Heart Fail. 2010; 12 (12): 1309-16. doi: 10.1093/eurjhf / hfq151.
62. Bettencourt P., Ferreira-Coimbra J., Rodrigues P. et al. Towards a multi-marker prognostic strategy in acute heart failure: a role for GDF-15. ESC Heart Fail. 2018. doi: 10.1002/ehf2.12301.
63. Khorolets E.V., Shlyk S.V. The features of GDF-15 in patients with acute myocardial infarction complicated by acute heart failure. In: VI Eurasian Congress of Cardiologists: Theses. Moscow, 2018: 39. (in Russian)
64. Kopitsa N.P., Vishnevskaya I. R. prediction of lethal outcome in patients with acute coronary syndrome in the near and distant periods. Sciencerisi. 2014; 5 (4): 7-10. doi: 10.15587/2313-8416.2014.31916. (in Russian)
65. Kempf T., Bjorklund E., Olofsson S., et al. Growth-differentiation factor-15 improves risk stratification in ST-segment elevation myocardial infarction. Eur Heart J. 2007; 28 (23): 2858-65. doi: 10.1093/eurheartj/ehm465.
66. Garcia-Garcia C., Rueda F., Lupon J., et al. Growth differentiation factor-15 is a predictive biomarker in primary ventricular fibrillation: the RUTI-STEMI-PVF study. Eur Heart J Acute Cardiovasc Care. 2018 Sep 3. doi: 10.1177/2048872618797599.
67. Wollert K.C., Kempf T., Peter T., et al. Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome. Circulation. 2007; 115 (8): 962-71.
68. Damman P., Kempf T., Windhausen F., et al. Growth-differentiation factor 15 for long-term prognostication in patients with non-ST-elevation acute coronary syndrome: an Invasive versus Conservative Treatment in Unstable coronary Syndromes (ICTUS) substudy. Int J Cardiol. 2014; 172 (2): 356-63. doi: 10.1016/j.ijcard.2014.01.025.
69. Sun L., Zhou X., Jiang J., et al. Growth differentiation factor-15 levels and the risk of contrast induced acute kidney injury in acute myocardial infarction patients treated invasively: a propensity-score match analysis. PLoS One. 2018; 13 (3). doi: 10.1371/journal.pone.0194152.
70. Kopitsa N.P. The role of growth factor of differentiation 15 in stratification of risk of kidney damage in acute coronary syndrome. Problemi suchasnoy meditsini: Visnik Ukrainskoy medichnoy stomatologichnoy akademii [Actual problems of modern medicine: Bulletin of the Ukrainian medical dental Academy]. 2017; 17 (1): 106-11. (in Russian)
71. Lindholm D., Hagström E., James S.K., et al. Growth differentiation factor 15 at 1 month after an acute coronary syndrome is associated with increased risk of major bleeding. J Am Heart Assoc. 2017; 6 (4). doi: 10.1161/JAHA.117.005580.